EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

by Elena Iemma | Nov 4, 2021 | News

PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...

AAPS NBC Tech Challenge Talk: Engineering Better Biologics: Does Nature Know Best?

by Elena Iemma | May 21, 2021 | Events, Webinars

EpiVax CEO/CSO Annie De Groot and Director of Analysis Frances Terry co-presented “Engineering Better Biologics: Does Nature Know Best?” at the 2021 AAPS NBC conference May 19th 2021. Outline:  Background on T cells / Immunogenicity EpiMatrix, JanusMatrix ...

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

by Elena Iemma | Apr 27, 2021 | News

PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising...

EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)

by Adam | Dec 15, 2020 | News

PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...

Webinar: Immune Engineering Human B cell-Derived Antibodies for Emerging Infectious Diseases

by Annie De Groot | May 1, 2020 | Events, Webinars

This webinar has passed but we invite you to view the recording below.  Please extend this invitation to any colleagues or associates you feel would benefit from attending. Participation is always free and open to all. We look forward to “seeing” you...